Lucentis 10 mg/ml solution for injection in pre-filled syringe clinical trials

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

This study looks at a new drug, OPT-302, combined with an existing treatment (Lucentis) for 'wet' age-related macular degeneration (AMD). It aims to see if the combination works better than Lucentis alone to improve or maintain vision over one year.